To support the updated U.S. Preventive Services Task Force recommendation in this issue, Hillier and colleagues reviewed the
evidence on the benefits and harms of screening for gestational diabetes mellitus. They found no randomized, controlled trials
that directly evaluated the risks and benefits, limited evidence suggesting that treatment after 24 weeks' gestation improves
some maternal and neonatal outcomes, and very limited evidence about early screening before 24 weeks' gestation.